*TARGET PGB (PEPTIDOGLYCAN BIOSYNTHESIS) IS THE FOCUS OF COLLABORATION
DESIGNED TO DEVELOP NOVEL FAMILY OF ANTIBACTERIAL DRUGS BASED ON HIGHLY
Hamburg, Germany and Cambridge, MA - 16 May 2013: Evotec AG today announced a research collaboration with Harvard University aimed at discovering and developing
novel anti-bacterial agents based on a highly validated target family
involved in bacterial cell wall biosynthesis.
- STRONG STRATEGIC POSITION SUPPORTS ACTION PLAN 2016 - INNOVATION
- EVOTEC'S DRUG DISCOVERY PLATFORM GENERATES GROWTH
- NEW HORMONE IDENTIFIED AS PART OF THE CUREBETA INITIATIVE
- GUIDANCE 2013 CONFIRMED
Hamburg, Germany - 14 May 2013: Evotec AG today reported financial results and corporate updates for the first quarter of 2013.- read more
Hamburg, Germany and Boston, MA - 30 April 2013: The Belfer Institute for
Applied Cancer Science at Dana-Farber Cancer Institute and Evotec AG
today announced a research collaboration aimed at discovering and commercialising novel
cancer treatments based on epigenetic drug mechanisms.
Hamburg, Germany - 29 April 2013: Evotec AG today announced that Evotec (US) Inc. has executed a multi-year lease on a facility specifically designed to expand
the offering of its Compound Management Services on the East Coast of the
Hamburg, Germany, 26 April 2013: Harvard University Prof. Doug Melton and his post doc Peng Yi describe the new hormone 'betatrophin' that controls beta cell proliferation as potential diabetes treatment.- read more
Hamburg, Germany - 22 April 2013: Evotec AG today announced that it has extended its drug discovery alliance with Genentech, a member of the Roche Group, for three additional years.- read more
Hamburg, Germany - 26 March 2013: Evotec AG today reported financial results and corporate updates for the fiscal year ended 31 December 2012.- read more
Hamburg, Germany - 18 March 2013: Evotec AG today announced that Dr Werner Lanthaler, Chief Executive Officer of Evotec, will resume his role as Chief Executive Officer of the Company with immediate effect after a period of leave due to health reasons.
Hamburg, Germany - 11 January 2013: Evotec AG today announced that a compound identified and optimised in a research collaboration with Ono Pharmaceutical Co., Ltd. has been nominated to enter pre-clinical development, leading to the payment of an agreed milestone.